A Phase 2 Randomized Double-blind, Placebo-controlled Clinical Trial of Intravenous Citrulline for Vaso-occlusive Pain Episode in Hospitalized Patients with Sickle Cell Disease (CONQUER SCD Pain Trial)

The goal of this clinical trial is to learn if intravenous citrulline works to treat acute pain in hospitalized patients with sickle cell disease. It will also learn about the safety of intravenous citrulline. The main questions it aims to answer are:
* Does intravenous citrulline decrease the duration of sickle cell pain during hospitalization
* What medical problems do participants have when taking intravenous citrulline? Researchers will compare intravenous citrulline to a placebo (a look-alike substance that contains no drug) to see if intravenous citrulline works to treat acute pain.
Participants will:
* Receive baseline tests and intravenous citrulline for 16 hours during the hospital stay
* After hospital discharge, visit the clinic in about 30 days for checkup and tests

开始日期2024-11-01

申办/合作机构

Children's National Research Institute

[+1]

NL-OMON56806 / SuspendedN/AIIT

Boosting the bone biology. The effect of oral L-citrulline supplementation on mesenchymal stem cell concentration and osteogenic potential of BMAC in healthy humans. A randomized open-label pilot study. - Boosting the bone biology

开始日期2024-02-01

申办/合作机构-

NCT06212765 / Not yet recruiting临床3期IIT

Effects of Oral Citrulline Supplementation on Fat-free Mass in COPD Patients With Malnutrition

Chronic obstructive pulmonary disease (COPD) is complicated by malnutrition in 20-70% of cases. In COPD, low fat-free mass is associated with a higher risk of morbidity and mortality. L-citrulline is a non-protein amino acid that has a direct effect on muscle protein synthesis. Oral supplementation with L-citrulline (10 g/day) in malnourished patients has shown to increase fat-free mass. The effects of L-citrulline supplementation in malnourished COPD patients are unknown.
The main objective of this prospective, single-centre, randomised, double-blind, placebo-controlled study will be to determine the impact of 45 days of nutritional supplementation with L-citrulline (10 g/day) on lean body mass (fat-free mass index (in kg.m-2) measured by bioelectrical impedance analysis) in malnourished patients (BMI < 20 kg/m2 if < 70 years old or < 22 kg/m2 if ≥ 70 years old) with COPD at stages 3-4 of the GOLD classification.

开始日期2024-01-25

申办/合作机构

Centre Hospitalier Universitaire de Grenoble

100 项与 L-Citrulline 相关的临床结果

登录后查看更多信息

100 项与 L-Citrulline 相关的转化医学

登录后查看更多信息

100 项与 L-Citrulline 相关的专利（医药）

登录后查看更多信息

366

项与 L-Citrulline 相关的文献（医药）

2024-05-01·Journal of Perinatology

Enteral L-citrulline supplementation in preterm infants is safe and effective in increasing plasma arginine and citrulline levels—a pilot randomized trial

Article

作者: Jain, Sunil K ; Bhatia, Snigdha ; Mehdi, Mohammad Q ; Franco-Fuenmayor, Maria E ; Qasim, Amna

OBJECTIVEDeficiencies of citrulline and arginine have been associated with adverse outcomes in preterm-infants and data regarding enteral supplementation in preterm infants is limited.STUDY DESIGNThis randomized -trial [NCT03649932] included 42 preterm infants (gestational age ≤33 weeks) randomized to receive enteral L-citrulline in low (100 mg/kg/day), medium (200 mg/kg/day) and high-dose (300 mg/kg/day) groups for 7 days. Plasma citrulline and arginine levels were obtained pre-and-post supplementation and efficacy was determined by a significant increase in levels after supplementation. A p < 0.05 was considered significant. Safety monitoring included blood-pressure-monitoring as well as complications and death during hospitalization.RESULTSA total of 40/42 (95%) of the recruits completed the 7-day supplementation with no adverse events. Plasma-citrulline levels increased significantly in all three groups while plasma-arginine levels increased significantly in the high-dose group.CONCLUSIONEnteral L-citrulline supplementation in preterm infants is safe and effective in increasing plasma citrulline and arginine levels.CLINICAL TRIAL REGISTRATIONNCT03649932 https://clinicaltrials.gov/ct2/show/NCT03649932 .

2024-03-01·Molecular Nutrition & Food Research

L‐Citrulline Ameliorates Iron Metabolism and Mitochondrial Quality Control via Activating AMPK Pathway in Intestine and Improves Microbiota in Mice with Iron Overload

Article

作者: Zhang, Yingsi ; Gao, Yuan ; Chen, Yiqin ; Dai, Hanchuan ; Zhao, Dai ; Niu, Sai ; Deng, Yian

ScopeOxidative stress caused by iron overload tends to result in intestinal mucosal barrier dysfunction and intestinal microbiota imbalance. As a neutral and nonprotein amino acid, L‐Citrulline (L‐cit) has been implicated in antioxidant and mitochondrial amelioration properties. This study investigates whether L‐cit can alleviate iron overload‐induced intestinal injury and explores the underlying mechanisms.Methods and resultsC57BL/6J mice are intraperitoneally injected with iron dextran, then gavaged with different dose of L‐cit for 2 weeks. L‐cit treatment significantly alleviates intestine pathological injury, oxidative stress, ATP level, and mitochondrial respiratory chain complex activities, accompanied by ameliorating mitochondrial quality control. L‐cit‐mediated protection is associated with the upregulation of Glutathione Peroxidase 4 (GPX4) expression, inhibition Nuclear Receptor Coactivator 4 (NCOA4)‐mediated ferritinophagy and ferroptosis, and improvement of gut microbiota. To investigate the underlying molecular mechanisms, Intestinal Porcine Epithelial Cell line‐J2 (IPEC‐J2) cells are treated with L‐cit or AMP‐activated Protein Kinase (AMPK) inhibitor. AMPK signaling has been activated by L‐cit. Notably, Compound C abolishes L‐cit's protection on intestinal barrier, mitochondrial function, and antioxidative capacity in IPEC‐J2 cells.ConclusionL‐cit may restrain ferritinophagy and ferroptosis to regulate iron metabolism, and induce AMPK pathway activation, which contributes to exert antioxidation, ameliorate iron metabolism and mitochondrial quality control, and improve intestinal microbiota. L‐cit is a promising therapeutic strategy for iron overload‐induced intestinal injury.

2024-03-01·Molecular Genetics and Metabolism

Impact of supplementation with L-citrulline/arginine after liver transplantation in individuals with Urea Cycle Disorders

Article

作者: Ramdhouni, Nesrine ; Gallagher, Renata C. ; Baumgartner, Matthias R. ; Le Mons, Cynthia ; Nagamani, Sandesh C.S. ; Konczal, Laura ; Lindner, Martin ; Druck, Ann-Catrin ; Ficicioglu, Can ; Wong, Derek ; Lam, Christina ; Berry, Gerard T. ; Gleich, Florian ; Dobbelaere, Dries ; Burrage, Lindsay C. ; Posset, Roland ; Gropman, Andrea L. ; McCandless, Shawn E. ; Schulze, Andreas ; Harding, Cary O. ; Seminara, Jennifer ; Zielonka, Matthias ; Stricker, Tamar ; Breilyn, Margo ; Mew, Nicholas Ah. ; Wilkening, Greta ; Diaz, George A. ; Kölker, Stefan ; Lawrence Merritt, J. ; Enns, Gregory M. ; Hoffmann, Georg F. ; García-Cazorla, Angeles ; Epp, Friederike ; Garbade, Sven F. ; Coughlin, Curtis R. ; Berry, Susan A.

OBJECTIVELiver transplantation (LTx) is an intervention when medical management is not sufficiently preventing individuals with urea cycle disorders (UCDs) from the occurrence of hyperammonemic events. Supplementation with L-citrulline/arginine is regularly performed prior to LTx to support ureagenesis and is often continued after the intervention. However, systematic studies assessing the impact of long-term L-citrulline/arginine supplementation in individuals who have undergone LTx is lacking to date.METHODSUsing longitudinal data collected systematically, a comparative analysis was carried out by studying the effects of long-term L-citrulline/arginine supplementation vs. no supplementation on health-related outcome parameters (i.e., anthropometric, neurological, and cognitive outcomes) in individuals with UCDs who have undergone LTx. Altogether, 52 individuals with male ornithine transcarbamylase deficiency, citrullinemia type 1 and argininosuccinic aciduria and a pre-transplant "severe" disease course who have undergone LTx were investigated by using recently established and validated genotype-specific in vitro enzyme activities.RESULTSLong-term supplementation of individuals with L-citrulline/arginine who have undergone LTx (n = 16) does neither appear to alter anthropometric nor neurocognitive endpoints when compared to their severity-adjusted counterparts that were not supplemented (n = 36) after LTx with mean observation periods between four to five years. Moreover, supplementation with L-citrulline/arginine was not associated with an increase of disease-specific plasma arithmetic mean values for the respective amino acids when compared to the non-supplemented control cohort.CONCLUSIONAlthough supplementation with L-citrulline/arginine is often continued after LTx, this pilot study does neither identify altered long-term anthropometric or neurocognitive health-related outcomes nor does it find an adequate biochemical response as reflected by the unaltered plasma arithmetic mean values for L-citrulline or L-arginine. Further prospective analyses in larger samples and even longer observation periods will provide more insight into the usefulness of long-term supplementation with L-citrulline/arginine for individuals with UCDs who have undergone LTx.

项与 L-Citrulline 相关的新闻（医药）

2023-10-05

·PRNewswire

Bizz Energy Is a Clean, Mean Way to Beat the Modern Midday Slump

The Energy Drink Formula Unleashes Unique Levels of Energy Whilst Avoiding Sugar Crashes and Unhealthy Ingredients FORT LAUDERDALE, Fla., Oct. 5, 2023 /PRNewswire/ -- The modern, remote-first work world may not have a consistent nine-to-five rhythm anymore. But that doesn't change the fact that people are still putting a lot of time into working their jobs. The Bureau of Labor Statistics reports that the average American worker clocks in at just over eight hours of labor per day (8.01, to be precise). That means, no matter when those work hours take place, they're going to extend over a significant portion of an individual's daily schedule. It also means it will involve a slump in energy and productivity at some point along the way. "Midday slumps may not always happen in the early afternoon anymore," says Gavin Jacono, founder of Bizz Energy, "But they happen at some point — and on a regular basis. If you start work at four in the morning, chances are you're going to lag after breakfast or in the late morning. If you start at noon, you'll feel tired before dinner." Northwestern Medicine points out that the biggest reason for this energy slump is that it's a predictable part of every individual's circadian cycle. However, the medical site adds that things like sleep disorders, stress, and even poor eating habits can also contribute to a slowdown in the middle of the workday. When that happens, many people turn to energy drinks as a solution — but Jacono points out that traditional energy drink formulas don't really solve the problem. "Those classic formulas use sugar, high fructose corn syrup, or aspartame. They give you a quick boost, but it's often followed by a crash — usually before your work day ends, which only means you're kicking the productivity issue down the road. And your body has to work through all of those unhealthy chemicals and additives, too. That's why we created Bizz Energy. To turn unhealthy, short-term energy drinks into healthy, long-term productivity and health solutions." Bizz Energy replaces unwanted ingredients with healthy alternatives. Each 12 oz can contains a clean shot of 200 mg of caffeine along with a punchy nutritional combination called the SuperTurk® blend. This includes an innovative soluble form of Turkesterone along with creatine, essential amino acids, L-citrulline, L-theanine, L-carnitine, niacin, and biotin. The result of this revolutionary combination is an energy drink that doubles as a nutritional supplement. It helps boost energy without a sugar crash while also stimulating metabolism and helping build muscle and strength. This makes it a clean, mean way to beat a midday slump — no matter when it might take place. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy

2023-08-04

·PRNewswire

Bizz Energy Clears Minds and Sharpens Focus

The Clean, Zero-Sugar Energy Drink Is Good For More Than Just Physical Performance. It Boosts Brain Function, Too. FORT LAUDERDALE, Fla., Aug. 4, 2023 /PRNewswire/ -- Bizz Energy is a revolutionary new zero-sugar energy drink designed to boost performance through natural ingredients without the use of harmful chemicals or additives. While this is primarily focused on physical activities, the energy supplement's ingredients can also deliver some helpful benefits for the brain. "I designed Bizz Energy to clear my mind as well as boost my physical performance," explains company founder Gavin Jacono. "Sometimes you need to do more than run faster, lift more, or stay awake longer. Sometimes you need that sharp focus that helps you deliver at work or in school." Bizz Energy helps with cognitive function through multiple natural ingredients. For instance, creatine is a safe brain and body amino acid that has been connected to short-term memory improvement when administered orally. L-citrulline has clearly demonstrated benefits for brain function, as well. L-Theanine relieves stress disorders, improves mood, and helps with sleep. Another ingredient with the potential to help with cognition is Turkesterone. While this popular supplement is currently trending in the sports and fitness world for its physical benefits, there are also suggestions that it could aid mental health by helping cope with stress and fatigue. "Including Turkesterone was a big deal for us," says Jacono. "I knew we wanted it in there, but it's a plant-based steroid, so it isn't water-soluble. We invested in extensive research and testing and were able to develop a method to solubilize Turkesterone — it's one of the most unique things about our product." From carefully selected amino acids to soluble Turkesterone, Bizz Energy is packed with natural ingredients designed to deliver a critical dose of energy when needed. The innovative combination of natural ingredients doesn't just apply to physical performance, either. It can be a game-changer when it comes to cognitive function, too, helping to sharpen the mind and create clear focus. About Bizz Energy Bizz Energy was founded by Gavin Jacono. The fitness and nutrition fanatic hails from New York City and is obsessed with boxing, weightlifting, and soccer. As an aspiring 17-year-old entrepreneur, Jacono launched Bizz Energy as a way to create the ultimate energy drink he had always wanted to fuel his athletic pursuits. Along with a potent dose of caffeine, the Bizz Energy formula taps into a unique form of soluble Turkesterone. It is delicious, clean, and effective. Learn more at bizzenergy.com. Media Contact: Gavin Jacono 516-637-8701 [email protected] SOURCE Bizz Energy

2023-01-15

·佰傲谷BioValley

双特异性ADC的兴起

随着ADC的快速发展，展现出具有强大的潜力，越来越多的企业进入ADC研发领域，也涌现出各种类型的ADC技术和分支。双特异性抗体偶联物（双特异性ADC）是其中一种逐渐兴起的新技术，利用双特异性抗体的高特异性，更精确靶向肿瘤细胞，另一方面通过交联作用促进两个靶点的协同内吞，可以提高毒素进入肿瘤细胞效率。目前，全球范围内双特异性ADC还处于早期发展阶段，仅有数款产品进入临床开发阶段，且均为早期临床。国内发展相较迅速，已经有三款双特异性ADC申报临床，此外还有一款同宜医药的双特异性的药物偶联物CBP-1008也申报临床了。领先的双特异ADC项目ZW49Zymeworks的Zanidatamab Zovodotin（ZW49）应该是双特异性ADC的代表产品，ZW49是基于其后期临床的HER2双抗Zanidatamab（ZW25）开发的管线，ZW49由结合两个非重叠HER2表位的非对称结构双抗（ECD4-曲妥珠，ECD2-帕妥珠表位），通过二硫键偶联auristatin而成。延伸阅读：Jazz获得HER2双抗zanidatamab，潜在交易额17.6亿美元ZW49目前正在进行一项1期临床试验，用于治疗局部晚期或转移性表达HER2的癌症患者。2021年1月，Zymeworks公司公布了ZW49的1期临床试验数据，数据显示：6名可评估的患者中，仅有2名患者确诊部分缓解和2名患者疾病稳定。尽管临床数据不达预期，但其具有积极的、差异化的安全性；在所有给药的患者中，没有剂量限制性毒性、没有治疗相关的血液学毒性，包括中性粒细胞减少或血小板减少症、没有治疗相关的肺毒性、包括间质性肺疾病或肺炎、没有治疗相关的肝毒性、没有与治疗有关的死亡。MEDI4276阿斯利康的MEDI4276是一款双表位四价HER2 ADC，以39S（表位类似于帕妥珠，全人源抗体，识别domain 2）为骨架，连接了trastuzumab（识别domain 4）的scFv结构。39S和曲妥珠单抗的识别表位位于HER2 ECD的相反端，彼此相距>90 Å。MEDI4276的DAR为4，linker为maleimidocaproyl linker，毒素为tubulysinwarhead。但是由于毒性问题，MEDI4276目前已经中止开发。REGN5093-M114Regenron有一款靶向MET两个不同表位的双抗ADC产品REGN5093-M114，由非对称型双特异抗体通过linker与毒素M24（美登素衍生物）连接，DAR值为3.2左右。值得注意的是，REGN5093-M114裸抗本身同样具有一定的抑制肿瘤的效果，并且在临床前的多种模型中展现了良好的药效。目前再生元已经将裸抗REGN5093和ADC双抗REGN5093-M114两种药物都推向了临床。M1231大多数双特异性ADC的靶点选择为同一靶点两个不同表位，例如以上的三款产品。但是，Merck（默克）的双特异性ADC管线M1231同时靶向EGFR/MUC1，MUCI/EGFR共表达在多种肿瘤细胞中，包括非小细胞肺癌（NSCLC）、食管鳞状细胞癌（ESCC）、头颈部鳞状细胞癌、三阴性乳腺癌和卵巢癌等。M1231基于SEED（链交换工程结构域）抗体支架开发，靶向MUCI的抗体部分为scFv，而靶向EGFR的抗体部分为Fab形式，DAR值约为4，通过可裂解的Val-Cit连接子与 hemiasterlin-related microtubule inhibitor 链接。在临床前研究中，M1231显示出对肿瘤细胞的有效载荷递送和积极的抗肿瘤活性。目前，M1231正在进行针对实体瘤的临床研究，尚未有数据公布。国内市场情况在双特异性ADC研发领域上，国内发展相较迅速，已经有三款双特异性ADC申报临床，此外还有一款同宜医药的双特异性的药物偶联物CBP-1008在临床申报。数据截止至2023年1月11日百利药业2021年8月10日，百利药业向NMPA申报了BL-B01D1的临床试验申请并获得受理；同年10月，BL-B01D1成为国内获得临床批准的双特异ADC药物。延伸阅读：首款双抗ADC获批临床，靶向EGFRxHER3百利药业是一家专注于开发多特异性抗体及ADC药物的创新药物公司，基于该公司GNC（Guidance navigation and control ）四特异性抗体技术平台，百利药业已经开发了多款多抗产品，并且有2款双抗和3款四抗获得临床批件。延伸阅读：百利药业四抗启动临床，中国生物药企在这一领域持续领先康宁杰瑞JSKN003是康宁杰瑞自主研发，基于HER2靶点的双抗偶联药物（ADC）。该ADC药物是在靶向HER2双抗KN026基础上设计和改造而来的，可同时结合HER2的两个非重叠表位，导致双HER2信号阻断，达到曲妥珠单抗和帕妥珠单抗联用的效果。2022年8月16日，CDE受理了JSKN003的临床试验申请，并于10月获得临床默示许可。此外，JSKN003正在澳大利亚进行一项多中心、开放式标签、剂量递增及首次人体研究的I期试验，以评估在晚期或转移性实体恶性肿瘤患者中的安全性及耐受性，并确定最大耐受剂量/II期推荐剂量。正大天晴2022年9月21日，CDE受理了TQB2102的临床试验申请；并于同年12月获得临床默示许可，用于治疗晚期恶性肿瘤。根据已披露的信息，正大天晴的TQB2102是一款氘代HER2双抗ADC，TQB2102可特异性结合HER2表达细胞上的HER2的ECD4表位的第一抗原结合片段（scFv）和ECD2表位的第二抗原结合片段（Fab），其payload采用喜树碱衍生物，核心为氘代DXd。延伸阅读：国内第二款！正大天晴HER2双抗ADC申报临床百奥赛图百奥赛图开发了基于RenLite平台的双抗ADC药物研发平台，利用共同轻链的方法防止双特异抗体轻链的错配，同时采用Knob-In-Hole防止抗体重链错配。在此基础上，其利用链间半胱氨酸进行偶联，linker为可裂解的二肽VC（valine-citrulline），毒素为MMAE。基于该平台，百奥赛图开发了一款双抗ADC，靶向HER2/Trop2 ，在体外人肿瘤细胞杀伤试验中，YH012显示具有强杀伤，且和单价抗体相比具有显著差异；同时，YH012的杀伤同样具有选择性。小结随着双抗技术的逐渐发展和成熟，基于双抗衍生的双特异性ADC开发策略也逐渐兴起。由于仅是起步阶段，靶点较为集中，以HER2为主要开发靶点；同时靶点选择也较少，或是靶向同一靶点不重叠表位，或是肿瘤细胞共表达的抗原；技术路线也不多。参考资料：1.https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-advances-her2-bispecific-antibody-drug-conjugate-zw492.BiG生物创新社《双抗ADC已悄悄上临床，让我们探探有哪些！》3.抗体密码《双抗的下一站：双抗ADC？》近期热门视频更多精彩视频，尽在佰傲谷视频号，欢迎关注~本周好文推荐如需转载请联系佰傲谷并在醒目位置注明出处﹀点亮在看，传递信息♥

抗体药物偶联物临床1期

100 项与 L-Citrulline 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07706	L-Citrulline	-	-

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性肺损伤	临床3期	奥地利	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	以色列	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	德国	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	德国	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	以色列	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	美国	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	奥地利	Asklepion Pharmaceuticals LLC	2016-08-01
急性肺损伤	临床3期	美国	Asklepion Pharmaceuticals LLC	2016-08-01
先天性心脏缺损	临床3期	美国	Asklepion Pharmaceuticals LLC	2006-05-01
肺性高血压	临床3期	美国	Asklepion Pharmaceuticals LLC	2006-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2023	N/A	-	-	L-citrulline	顧積窪網憲願齋遞遞願(選窪鏇壓積顧範簾積餘) = 選積獵膚醖積餘糧憲製願廠鬱鏇鑰簾廠構製顧 (窪淵壓膚鏇鬱淵鹹艱鑰 ) 更多	-	2023-05-21
				L-citrulline (Control (no treatment))	顧積窪網憲願齋遞遞願(選窪鏇壓積顧範簾積餘) = 願製願淵構醖壓襯鹽齋願廠鬱鏇鑰簾廠構製顧 (窪淵壓膚鏇鬱淵鹹艱鑰 ) 更多
NCT04570384 (CTgov)	临床2期	低氧性呼吸衰竭 \| 新型冠状病毒感染 \| COVID-19 呼吸道感染	65	L-Citrulline (IV L-Citrulline (Turnobi) Arm)	壓糧淵繭衊壓鹹願壓糧(廠鏇醖蓋蓋餘齋遞網鹽) = 膚獵壓餘醖積築鏇窪顧鬱網廠鹹醖蓋衊鹽蓋選 (獵繭鹹廠衊醖鏇艱積鬱, 壓壓繭鏇窪鑰齋積繭顧 ~ 齋餘蓋鑰膚蓋鑰獵窪獵) 更多	-	2023-02-22
				Placebo (Placebo Arm)	壓糧淵繭衊壓鹹願壓糧(廠鏇醖蓋蓋餘齋遞網鹽) = 憲鹹醖簾餘顧蓋遞鹹範鬱網廠鹹醖蓋衊鹽蓋選 (獵繭鹹廠衊醖鏇艱積鬱, 鏇鹽餘憲簾構糧選憲醖 ~ 鹽夢簾醖選襯襯構鹽積) 更多
NCT03542812 (Pubmed)	早期临床1期	支气管肺发育不良 \| 肺动脉高压	16	L-Citrulline	(餘網觸製淵遞鑰夢選憲) = 選鏇鏇壓鬱鏇願願簾蓋糧選膚膚觸願獵蓋憲製 (鏇鹹願鹽繭廠膚鏇網廠 ) 更多	-	2022-10-31
NCT01120964 (CTgov)	临床1/2期	房室间隔缺损 \| 心房中隔缺损 \| 心脏室间隔缺损	22	Intravenous L-Citrulline (Intravenous L-Citrulline)	齋餘糧壓獵遞顧鏇膚餘(衊簾壓壓廠鏇餘鹹壓積) = 鹹繭築網構鏇醖窪窪網觸構簾鑰鹽繭廠窪艱膚 (網範淵構製鹹築築廠鬱, 艱齋築簾網糧鑰齋鑰顧 ~ 構願齋簾鬱網夢顧糧夢) 更多	-	2022-06-21
				Placebo of Intravenous L-Citrulline (Placebo of Intravenous L-Citrulline)	齋餘糧壓獵遞顧鏇膚餘(衊簾壓壓廠鏇餘鹹壓積) = 獵範構願鏇鬱簾衊製製觸構簾鑰鹽繭廠窪艱膚 (網範淵構製鹹築築廠鬱, 觸築選願夢顧鬱觸簾壓 ~ 蓋壓夢蓋鹹鏇醖鏇醖窪) 更多
NCT01386034 (Pubmed \| Clin Nutr)	临床3期	短肠综合征	9	Citrulline supplementation	膚簾繭窪選製糧築築簾(遞艱鹽襯選鬱膚鑰夢齋) = 憲網網餘築膚鑰鹹簾襯獵觸壓膚鏇壓繭鏇艱鹽 (願鹽構構觸淵淵糧願範 ) 更多	-	2019-12-01
				citrulline (Placebo)	膚簾繭窪選製糧築築簾(遞艱鹽襯選鬱膚鑰夢齋) = 醖糧選齋製選範廠齋餘獵觸壓膚鏇壓繭鏇艱鹽 (願鹽構構觸淵淵糧願範 ) 更多
NCT02697240 (CTgov)	临床1期	血管闭塞危机 \| 急性胸部综合征	4	Intravenous citrulline	糧獵窪齋夢窪願艱遞觸(鏇鹽艱網夢齋選願積糧) = 齋願窪遞醖蓋觸繭淵齋範醖積餘憲願顧積鑰餘 (餘獵網膚壓壓獵簾製積, 壓繭膚積積醖襯鏇網憲 ~ 鑰蓋顧餘襯鹽糧獵觸廠) 更多	-	2019-04-17
NCT01474863 (CTgov)	临床2期	急性肺损伤 \| 脓毒症	72	Low Dose Citrulline (Low Dose Citrulline)	製範醖範網鏇顧獵艱齋(築範築鹽廠衊積積鑰遞) = 觸製獵壓選獵膚繭繭簾鹽範鬱糧壓夢鑰觸鑰獵 (鑰膚憲範憲網範範壓積, 餘衊膚鹹夢鬱廠顧窪願 ~ 願艱遞獵簾簾壓構蓋廠) 更多	-	2017-06-05
				Placebo (Placebo)	製範醖範網鏇顧獵艱齋(築範築鹽廠衊積積鑰遞) = 顧鏇餘齋築壓鏇鑰醖憲鹽範鬱糧壓夢鑰觸鑰獵 (鑰膚憲範憲網範範壓積, 糧衊鏇艱選構淵糧窪顧 ~ 積廠積鹹網遞廠積壓範) 更多
NCT02314689 (CTgov)	临床1期	镰状细胞血症	4	Intravenous (IV) citrulline	鹹築鑰淵積鹹鑰餘選襯(淵襯鬱鏇夢遞糧餘鏇淵) = 獵窪鏇蓋積蓋壓窪遞鹽壓築遞繭鏇齋製鑰網築 (繭範獵鑰築範窪襯窪蓋, 鹹願艱壓憲選觸築蓋鑰 ~ 廠遞憲餘鏇窪膚願醖襯)	-	2016-03-07
Pubmed \| J Nutr	N/A	胎儿生长受限	-	L-Citrulline	選觸艱鬱壓鑰糧繭壓糧(壓繭顧鏇獵艱鹹壓簾鹹) = 製醖選蓋鹹遞醖鹽簾選鏇艱夢衊鹽獵選願膚糧 (遞糧簾選衊壓構鏇壓遞 )	-	2016-03-01
				L-Citrulline	選觸艱鬱壓鑰糧繭壓糧(壓繭顧鏇獵艱鹹壓簾鹹) = 選壓夢齋憲鑰鬱鑰壓蓋鏇艱夢衊鹽獵選願膚糧 (遞糧簾選衊壓構鏇壓遞 )